Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer
Sponsor: University of Michigan Rogel Cancer Center
Listed as NCT01633541, this PHASE2 trial focuses on Laryngeal Cancer and remains completed. Sponsored by University of Michigan Rogel Cancer Center, it has been updated 15 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Aug 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 10 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Michigan Rogel Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Ann Arbor, United States